SCHEMBL1887643

SCHEMBL1887643

CN(C)CCOc1ccc(Nc2nc(-c3ccncc3)cs2)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 10/20 0.60
RAB9A P51151 9/20 0.60
MEN1 O00255 8/20 0.60
KMT2A Q03164 8/20 0.60
NPC1 O15118 7/20 0.60
ALOX5 P09917 4/20 0.57
SMN1; SMN2 Q16637 5/20 0.56
PTGS2 P35354 2/20 0.56
VCP P55072 2/20 0.56
ESR1 P03372 1/20 0.56
POLB P06746 1/20 0.56
TDP1 Q9NUW8 1/20 0.56
GAA P10253 5/20 0.55
ALDH1A1 P00352 5/20 0.55
HTT P42858 2/20 0.55
LMNA P02545 2/20 0.55
NPSR1 Q6W5P4 2/20 0.55
NFKB1 P19838 3/20 0.53
NFKB2 Q00653 3/20 0.53
RELA Q04206 3/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14458450 0.86 CYP1A2 (0.64) MAPTRAB9AMEN1KMT2ANPC1
SCHEMBL12297313 0.84 ALOX5 (0.77) MAPTRAB9AMEN1KMT2ANPC1
SCHEMBL206383 0.84 RAB9A (0.60) MAPTRAB9AMEN1KMT2ANPC1
SCHEMBL206286 0.84 RAB9A (0.60) MAPTRAB9AMEN1KMT2ANPC1
SCHEMBL1880690 0.82 MAPT (0.64) MAPTRAB9AMEN1KMT2ANPC1
SCHEMBL7476936 0.80 IKBKB (0.72) MEN1KMT2AHDAC6IKBKB
SCHEMBL1889521 0.80 PTGS2 (0.86) MAPTRAB9AMEN1KMT2ANPC1
SCHEMBL11880071 0.79 CYP1A2 (0.55) SMN1; SMN2ALDH1A1IKBKB
SCHEMBL12297398 0.77 MAPT (0.74) MAPTRAB9AMEN1KMT2ANPC1
SCHEMBL1819321 0.77 RAB9A (0.70) MAPTRAB9AMEN1KMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110105436-A1 HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE IN CANCER TREATMENT AUCKLAND UNISERVICES LIMITED (NZ) 2011-05-05 US claimed
US-20110105436-A1 HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE IN CANCER TREATMENT AUCKLAND UNISERVICES LIMITED (NZ) 2011-05-05 US disclosed
US-20110105436-A1 HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE IN CANCER TREATMENT AUCKLAND UNISERVICES LIMITED (NZ) 2011-05-05 US disclosed
US-20110105436-A1 HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE IN CANCER TREATMENT AUCKLAND UNISERVICES LIMITED (NZ) 2011-05-05 US disclosed
WO-2009114552-A1 HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE IN CANCER TREATMENT THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2009-09-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110105436-A1 HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE IN CANCER TREATMENT VHL, TP53, BECN1 MAPT 2506/4885RAB9A 508/4885MEN1 3092/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.